user

Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta

被引：31
|
作者：
Gotherstrom, Cecilia [1 ]
Walther-Jallow, Lilian [1 ]
机构：
[1] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Obstet & Gynecol, ANA Futura, Floor 8,Alfred Nobels Alle 8, S-14152 Stockholm, Sweden
来源：
CURRENT OSTEOPOROSIS REPORTS | 2020年 / 18卷 / 04期
基金：
瑞典研究理事会; 欧盟地平线“2020”;
关键词：
Osteogenesis imperfecta; Brittle bones; Stem cell therapy; Stem cell transplantation; Prenatal therapy; Mesenchymal stem cells; MESENCHYMAL STROMAL CELLS; IN-UTERO TRANSPLANTATION; INTRAUTERINE TRANSPLANTATION; IMMUNOLOGICAL-PROPERTIES; MUSCLE DIFFERENTIATION; FETAL; BONE; CLASSIFICATION; PHENOTYPE; RESPONSES;
D O I：
10.1007/s11914-020-00594-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of Review Osteogenesis imperfecta (OI) is a chronic disease with few treatment options available. The purpose of this review is to provide an overview on treating OI with mesenchymal stem cells (MSC). Recent Findings Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and are easy to manufacture. Their ability to migrate, engraft, and differentiate into bone cells, and also to act via paracrine effects on the recipient's tissues, makes MSC candidates as a clinical therapy for OI. Due to their high osteogenic potency, fetal MSC offer an even higher therapeutic potential in OI compared with MSC derived from adult sources. Preclinical and initial clinical data support the use of MSC in treating OI. The characteristics of MSC make them of great interest in treating OI. MSC may be safely transplanted via intravenous administration and show potential positive clinical effects.
引用
收藏
页码：337 / 343
页数：7
相关论文
共 50 条
  • [21] Osteogenesis Imperfecta: Diagnosis and Treatment
    A. Biggin
    C. F. Munns
    [J]. Current Osteoporosis Reports, 2014, 12 : 279 - 288
  • [22] Osteogenesis imperfecta [Osteogenesis imperfecta]
    Salzmann M.
    Krohn C.
    Berger N.
    [J]. Der Orthopäde, 2014, 43 (8): : 764 - 771
  • [23] Medical treatment of osteogenesis imperfecta
    Plotkin, H
    Glorieux, FH
    [J]. DRUG DEVELOPMENT RESEARCH, 2000, 49 (03) : 141 - 145
  • [24] OSTEOGENESIS IMPERFECTA, TREATMENT WITH BIOPHOSPHONATES
    Tau, Cristina
    [J]. ACTUALIZACIONES EN OSTEOLOGIA, 2008, 4 (01) : 22 - 29
  • [25] Osteogenesis Imperfecta: Diagnosis and Treatment
    Biggin, A.
    Munns, C. F.
    [J]. CURRENT OSTEOPOROSIS REPORTS, 2014, 12 (03) : 279 - 288
  • [26] Potential of Human Fetal Chorionic Stem Cells for the Treatment of Osteogenesis Imperfecta
    Jones, Gemma N.
    Moschidou, Dafni
    Abdulrazzak, Hassan
    Kalirai, Bhalraj Singh
    Vanleene, Maximilien
    Osatis, Suchaya
    Shefelbine, Sandra J.
    Horwood, Nicole J.
    Marenzana, Massimo
    De Coppi, Paolo
    Bassett, J. H. Duncan
    Williams, Graham R.
    Fisk, Nicholas M.
    Guillot, Pascale V.
    [J]. STEM CELLS AND DEVELOPMENT, 2014, 23 (03) : 262 - 276
  • [27] Osteogenesis imperfecta: pathophysiology and treatment
    Hoyer-Kuhn, Heike
    Netzer, Christian
    Semler, Oliver
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (13-14) : 278 - 284
  • [28] Treatment with bisphosphonates of osteogenesis imperfecta
    Kocova, Mirjana
    Sukarova-Angelovska, Elena
    [J]. HORMONE RESEARCH, 2008, 70 : 247 - 247
  • [29] Treatment options for osteogenesis imperfecta
    Besio, Roberta
    Forlino, Antonella
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (02): : 165 - 181
  • [30] Treatment of children with osteogenesis imperfecta
    Rauch F.
    Glorieux F.H.
    [J]. Current Osteoporosis Reports, 2006, 4 (4) : 159 - 164
12345